Comparative Pharmacology
Head-to-head clinical analysis: ENSTILAR versus PALSONIFY.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ENSTILAR versus PALSONIFY.
ENSTILAR vs PALSONIFY
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
ENSTILAR is a combination of calcipotriene (a vitamin D analog) and betamethasone dipropionate (a corticosteroid). Calcipotriene binds to vitamin D receptors, modulating cell proliferation and differentiation. Betamethasone suppresses inflammation by inhibiting phospholipase A2, reducing prostaglandin and leukotriene synthesis.
Selective serotonin reuptake inhibitor (SSRI) that enhances serotonergic neurotransmission by blocking the reuptake of serotonin at the presynaptic neuron, thereby increasing extracellular serotonin levels in the brain.
Apply to affected area once daily for up to 4 weeks. Maximum 100 g/day or 30 g/week. Not for use on face, axillae, or groin.
70 mg/m2 IV every 3 weeks. Infusion over 60 minutes.
None Documented
None Documented
Calcipotriol: terminal half-life ~12 hours. Betamethasone dipropionate: terminal half-life ~16-22 hours. Clinically, this supports once-daily application.
Terminal half-life 12 hours (range 10–14 h) in healthy adults; prolonged to 24–30 h in severe renal impairment (CrCl <30 mL/min)
Calcipotriol is primarily excreted via bile/feces (approximately 70% of absorbed dose). Betamethasone dipropionate is mainly excreted renally (60-70% as metabolites) and up to 20-30% via feces. For the combination, renal excretion of betamethasone metabolites predominates, with fecal excretion of calcipotriol.
Renal: 65% unchanged; biliary/fecal: 30% as metabolites; 5% other
Category C
Category C
Topical Corticosteroid and Vitamin D Analog
Topical Corticosteroid